应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PBLS Parabilis Medicines
盘后交易 06-12 16:05:34 EDT
27.26
-3.05
-10.06%
盘后
27.26
+0.00
0.00%
16:04 EDT
最高
32.47
最低
26.88
成交量
103.54万
今开
29.86
昨收
30.31
日振幅
18.44%
总市值
32.21亿
流通市值
6.82亿
总股本
1.18亿
成交额
2,995万
换手率
4.14%
流通股本
2,500万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Parabilis Medicines宣布完成规模扩大的首次公开募股,承销商全额行使超额配售权
美股速递 · 06-12 04:06
Parabilis Medicines宣布完成规模扩大的首次公开募股,承销商全额行使超额配售权
异动解读|Parabilis Medicines盘中上涨49.15%,IPO首日获10倍超额认购大幅高开
行情直击 · 06-11 02:03
异动解读|Parabilis Medicines盘中上涨49.15%,IPO首日获10倍超额认购大幅高开
异动解读 | 美股IPO上市受热捧,Parabilis Medicines盘中大涨66.75%
异动解读 · 06-11 01:12
异动解读 | 美股IPO上市受热捧,Parabilis Medicines盘中大涨66.75%
美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%
智通财经 · 06-11 00:00
美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%
癌症肽疗法新星Parabilis(PBLS.US)超区间定价IPO,获10倍超额认购 最终募资7.45亿美元
智通财经 · 06-10 11:30
癌症肽疗法新星Parabilis(PBLS.US)超区间定价IPO,获10倍超额认购 最终募资7.45亿美元
暂无数据
公司概况
公司名称:
Parabilis Medicines
所属市场:
NASDAQ
上市日期:
--
主营业务:
Parabilis Medicines, Inc.于2015年7月10日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,旨在开发变革性药物,解决历史上驱动人类疾病的不可药物蛋白靶点。其专有平台开创了Helicons,稳定的螺旋肽被设计用于细胞渗透,能够以高特异性结合扁平的细胞内蛋白质目标表面。
发行价格:
--
{"stockData":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":27.26,"timestamp":1781294400000,"preClose":30.31,"halted":0,"volume":1035390,"hourTrading":{"tag":"盘后","latestPrice":27.26,"preClose":27.26,"latestTime":"16:04 EDT","volume":185,"amount":5077.100595,"timestamp":1781294687094,"change":0,"changeRate":0,"amplitude":0.012472},"delay":0,"changeRate":-0.10062685582316058,"floatShares":25000000,"shares":118145780,"eps":-67.08582,"marketStatus":"盘后交易","change":-3.05,"latestTime":"06-12 16:05:34 EDT","open":29.86,"high":32.47,"low":26.88,"amount":29945025,"amplitude":0.184428,"askPrice":30.14,"askSize":50,"bidPrice":26.5,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-67.08582,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781308800000},"marketStatusCode":4,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":30.31,"preHourTrading":{"tag":"盘前","latestPrice":29.7757,"preClose":30.31,"latestTime":"08:28 EDT","volume":4048,"amount":121730.27803199999,"timestamp":1781267281231,"change":-0.5343,"changeRate":-0.017628,"amplitude":0.040901},"postHourTrading":{"tag":"盘后","latestPrice":27.26,"preClose":27.26,"latestTime":"16:04 EDT","volume":185,"amount":5077.100595,"timestamp":1781294687094,"change":0,"changeRate":0,"amplitude":0.012472},"volumeRatio":0.291776},"requestUrl":"/m/hq/s/PBLS/tweets","defaultTab":"tweets","newsList":[{"id":"1189403882","title":"Parabilis Medicines宣布完成规模扩大的首次公开募股,承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1189403882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189403882?lang=zh_cn&edition=full","pubTime":"2026-06-12 04:06","pubTimestamp":1781208398,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布,其规模扩大的首次公开募股(IPO)已正式完成。此次发行中,承销商全额行使了购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120727250","title":"异动解读|Parabilis Medicines盘中上涨49.15%,IPO首日获10倍超额认购大幅高开","url":"https://stock-news.laohu8.com/highlight/detail?id=1120727250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120727250?lang=zh_cn&edition=full","pubTime":"2026-06-11 02:03","pubTimestamp":1781114598,"startTime":"0","endTime":"0","summary":"6月10日,Parabilis Medicines盘中上涨49.15%,报29.83美元/股,成交额1.01亿美元。消息面上,公司当日完成美股IPO并挂牌上市,发行价定为每股20美元,高于此前17-19美元的推介区间,IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股,募资约6.70亿美元;同时再生元制药以每股18美元认购约7500万美元股份,合计筹资近7.45亿美元。Parabilis Medicines是一家临床阶段生物制药公司,专注于开发用于癌症治疗的工程化肽疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104824154","title":"异动解读 | 美股IPO上市受热捧,Parabilis Medicines盘中大涨66.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104824154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104824154?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:12","pubTimestamp":1781111553,"startTime":"0","endTime":"0","summary":"生物科技公司Parabilis Medicines 今日盘中股价大幅飙升66.75%,成为市场焦点。Parabilis Medicines成立于2015年,专注于开发针对多种癌症及罕见肿瘤的治疗方案,此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段,这增强了投资者对公司未来发展的信心。市场分析认为,尽管公司目前处于亏损状态,但其在癌症治疗领域的专业性和IPO带来的资金注入,为其后续的研发和商业化提供了关键支持,从而推动了股价的积极表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478833","title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642478833?lang=zh_cn&edition=full","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周三,聚焦癌症治疗的美国生物科技公司Parabilis Medicines(PBLS.US)登陆美股市场,开盘股价走高,截至发稿,该股涨44.35%,报28.87美元。IPO价格为20美元。Parabilis成立于2015年,专注于开发用于多种癌症及罕见肿瘤的治疗方案。公司拟将IPO募集资金用于推进其最领先候选药物zolucatetide进入更后期临床试验阶段。截至2025财年年末,Parabilis净亏损1.459亿美元,期末现金及现金等价物2,770万美元;前一财年净亏损为1.179亿美元,现金为4,730万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414058","title":"癌症肽疗法新星Parabilis(PBLS.US)超区间定价IPO,获10倍超额认购 最终募资7.45亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414058?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:30","pubTimestamp":1781062200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,聚焦癌症治疗的美国生物科技公司Parabilis Medicines完成了一项规模上调的美股IPO,发行价定在推介区间之上,叠加同步进行的私募配售,合计筹资近 7.45亿美元。在本次周二上调规模前,IPO认购需求已达可供股份数的约10倍。文件显示,截至 2025财年年末,Parabilis 净亏损 1.459亿美元,期末现金及现金等价物 2,770万美元;前一财年净亏损为 1.179亿美元,现金为 4,730万美元。Parabilis 成立于 2015年,专注于开发用于多种癌症及罕见肿瘤的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.parabilismed.com","stockEarnings":[{"period":"1week","weight":0.5155},{"period":"ytd","weight":0.5155}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Parabilis Medicines, Inc.于2015年7月10日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,旨在开发变革性药物,解决历史上驱动人类疾病的不可药物蛋白靶点。其专有平台开创了Helicons,稳定的螺旋肽被设计用于细胞渗透,能够以高特异性结合扁平的细胞内蛋白质目标表面。","exchange":"NASDAQ","name":"Parabilis Medicines","nameEN":"Parabilis Medicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Parabilis Medicines(PBLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Parabilis Medicines(PBLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Parabilis Medicines,PBLS,Parabilis Medicines股票,Parabilis Medicines股票老虎,Parabilis Medicines股票老虎国际,Parabilis Medicines行情,Parabilis Medicines股票行情,Parabilis Medicines股价,Parabilis Medicines股市,Parabilis Medicines股票价格,Parabilis Medicines股票交易,Parabilis Medicines股票购买,Parabilis Medicines股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Parabilis Medicines(PBLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Parabilis Medicines(PBLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}